Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Nature Medicine

Volumn 18, Issue 7, 2012, Pages 1118-1122

  Kentsis, Alex ^a,b   Reed, Casie ^a,b   Rice, Kim L ^c   Sanda, Takaomi ^a,b   Rodig, Scott J ^d   Tholouli, Eleni ^e   Christie, Amanda ^a,b,f   Valk, Peter J M ^g   Delwel, Ruud ^g   Ngo, Vu ^h   Kutok, Jeffery L ^d   Dahlberg, Suzanne E ^f   Moreau, Lisa A ^a,b   Byers, Richard J ^e,i   Christensen, James G ^j   Woude, George Vande ^k   Licht, Jonathan D ^c   Kung, Andrew L ^a,b,f   Staudt, Louis M ^l   Thomas Look, A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j PFIZER INC   (United States)

^k VAN ANDEL RESEARCH INSTITUTE   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CELL GROWTH; CELL KILLING; CELL SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; LEUKEMIA, MYELOID, ACUTE; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REMISSION INDUCTION;

EID: 84863728707     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2819     Document Type: Article

References (26)

1. Grimwade, D. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312-1320 (2001).
2. Burnett, A., Wetzler, M. & Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487-494 (2011).
3. Westbrook, T.F., Stegmeier, F. & Elledge, S.J. Dissecting cancer pathways and vulnerabilities with RNAi. Cold Spring Harb. Symp. Quant. Biol. 70, 435-444 (2005). (Pubitemid 44124899)
4. Bernards, R., Brummelkamp, T.R. & Beijersbergen, R.L. shRNA libraries and their use in cancer genetics. Nat. Methods 3, 701-706 (2006). (Pubitemid 44275737)
5. Ngo, V.N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
6. Whitehurst, A.W. et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007). (Pubitemid 46582032)
7. Turner, N.C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008). (Pubitemid 351655175)
8. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
9. Gu, T.L. et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 108, 4202-4204 (2006).
10. Wang, C., Curtis, J.E., Minden, M.D. & McCulloch, E.A. Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3, 264-269 (1989). (Pubitemid 19092758)
11. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G.F. MET, metastasis, motility, and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003).
12. Valk, P.J. et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004). (Pubitemid 38528701)
13. Zou, H.Y. et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007). (Pubitemid 46815090)
14. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998). (Pubitemid 28474784)
15. Sporn, M.B. & Todaro, G.J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303, 878-880 (1980).
16. Loriaux, M.M. et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111, 4788-4796 (2008).
17. Haq, R. et al. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res. 62, 5076-5082 (2002). (Pubitemid 34987550)
18. Majeti, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. USA 106, 3396-3401 (2009).
19. Robinson, D.R., Wu, Y.M. & Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene 19, 5548-5557 (2000).
20. Zheng, R., Klang, K., Gorin, N.C. & Small, D. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. Leuk. Res. 28, 121-126 (2004). (Pubitemid 37487991)
21. Zhou, J. et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113, 4052-4062 (2009).
22. Sato, T. et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286-3293 (2011).
23. Ngo, V.N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110 (2006).
24. Heinrichs, S. et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23, 1605-1613 (2009).
25. Mathew, P. et al. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia 3, 105-109 (2001). (Pubitemid 32410350)
26. Armstrong, S.A. et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183 (2003). (Pubitemid 37443389)